Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Illumina Launches New Reagent Kits for the MiSeq® System

Published: Thursday, August 22, 2013
Last Updated: Thursday, August 22, 2013
Bookmark and Share
Latest milestone doubles sequencing output to 15Gb, enables applications including exome sequencing.

Illumina, Inc. has announced the availability of its newest reagent kits for the MiSeq, the industry's most accurate and easiest-to-use benchtop sequencer.

The improved chemistry doubles sequencing output to 15 gigabases (Gb) by increasing the number of sequencing reads (up to 25 million reads) and overall read length (up to 2x300 base pairs).

These innovations enable researchers to perform new applications including exome sequencing on the MiSeq.

In addition, increased sequencing reads will support transcriptome applications such as mRNA sequencing and will offer higher throughput capacity for gene expression profiling with Illumina's TruSeq Targeted RNA Expression assay.

The benefits of increased paired-end read lengths include improving the quality of genome assemblies and advancing applications that require longer read lengths, such as metagenomics and human leukocyte antigen (HLA) typing.

"The new MiSeq kits are another example of how we are focused on continually improving the performance and value of our sequencing platforms for our customers," said Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions business.

Henry continued, "The latest MiSeq system enhancements deliver the highest data quality and will open up new applications for researchers in markets as diverse as cancer, genetic disease, microbiology, agriculture and forensics."

Added Dr. Ellen Heitzer of the Institute for Human Genetics, Medical University of Graz in Austria, "As a beta customer, we have seen even more robust MiSeq performance with the new chemistry, including the ability to pool more samples for our circulating tumor assay. We've also seen excellent sequencing quality, with almost 90 percent of clusters passing the filter and 96 percent of reads with a quality score greater than 30. In addition, the longer read length will facilitate the identification of translocations and fusion genes for our target resequencing approaches."

The new MiSeq reagent kits are now shipping, including a 600-cycle kit and a 150-cycle kit. For more information visit,

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Illumina Announces Oncology CDx Partnership with AstraZeneca, Janssen and Sanofi
Illumina, forms collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system.
Thursday, August 21, 2014
Illumina Appoints Senior VP of Oncology
Company names Tina S. Nova as Senior Vice President and General Manager of oncology.
Tuesday, July 15, 2014
Amgen and Illumina Enter Agreement
Illumina to develop IVD kit on its FDA-cleared MiSeqDx™ NGS instrument for Amgen’s Vectibix (Panitumumab).
Monday, January 20, 2014
Illumina Technology Enables Findings of COGS
Custom iSelect® genotyping array designed in collaboration with consortia to advance understanding of cancer.
Tuesday, May 28, 2013
Caris Life Sciences Selects Illumina’s MiSeq® System
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.
Friday, November 09, 2012
Illumina Announces Scale-Up of Genome Analyzers at the Broad Institute
Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.
Friday, November 06, 2009
Illumina Advances Genetic Analysis of Cancer
Illumina is launching software tools that enable customers to use Infinium™ SNP genotyping data.
Friday, December 16, 2005
Scientific News
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos